与「Clinical」相关的搜索结果

Rough back of the envelope math: if 40% of US physicians are OpenEvidence DAUs and there's ~22 workdays a month, 42m queries in August implies ~5 queries per workday day per physician (Google is ~4.2 searches per day and ChatGPT is ~2.5 queries per day). This kind of pulse on real-time clinical uncertainty is remarkable. Imagine you could now categorize those queries: see for which flavors of clinical uncertainty existing knowledge / solutions are most scant (or don't exist at all) and then plug in that knowledge / those solutions, fund studies / initiatives to create that knowledge / those solutions, etc. You see how OpenEvidence's flywheel will start to spin a lot faster than the labs in terms of capabilities. It's all about your product enumerating demand in some valuable subset of economic reality faster than competitors. In this case, OpenEvidence enumerates physician demand for information / capabilities that can help solve patient problems. They do this faster and with higher fidelity than anyone else. This is incredibly valuable.

My dear friends, I am happy to report the publication of the most important paper in my life to date (we have several great papers coming out but this is very special). Tomorrow, I will present this paper for the first time at the Nature AI Healthcare in Paris and will post a longer post on this story and its broader implications for how to conduct clinical trials. Please read it and comment on it. Many thanks to the great co-authors of the study and everyone who contributed. Many thanks to the many reviewers (friendly and unfriendly) for spending so much time and helping make it better. Link in the comments.

Grok 4.6 just took the #1# spot on MedAgentBench....one of the most interesting benchmarks for real-world agentic healthcare tasks and Grok now has two generations sitting in the top 3 • #1# Grok 4.6 — ~95.9% • #2# GPT-5.6 Sol — ~94.7% • #3# Grok 4.5 — ~93.4% MedAgentBench goes far beyond answering medical questions It tests AI agents on 300 clinically derived tasks across 10 categories inside a realistic electronic health-record environment, requiring the model to reason, use tools and actually execute multi-step clinical workflows Grok 4.5 was already one of the strongest medical agents tested. Grok 4.6 just pushed it to another level Grok is rapidly becoming one of the strongest AI model families for agentic healthcare work

🥇 We evaluated Grok 4.6 on MedAgentBench, a benchmark for agentic clinical EHR tasks, and it took the top spot. Grok 4.6 posts the highest pass@1 we've measured to date, moving ahead of the previous leader, GPT-5.6 Sol, to claim first place on the leaderboard. 🏥 Grok 4.6 averages ~95.9% pass@1 (avg of 3 runs), edging out the prior best (GPT-5.6-sol at ~94.7%) and improving on Grok 4.5 by roughly 2.5 points. On a benchmark where the model acts as an autonomous agent in a simulated EHR, calling FHIR APIs to complete clinical tasks across 10 task types, the result is also remarkably consistent run to run (95.3% to 96.3%). 📊 Leaderboards:

Grok 4.6 just broke into the Top 3 on the Artificial Analysis Healthcare & Medical Index Grok 4.6 (high) scores 50 - just ONE point off the top score of 51 It outperforms GPT-5.6 Sol, Kimi K3 and Gemini 3.7 Flash This index measures how models actually handle healthcare and medical work: • Medical and health knowledge • Clinical reasoning • Patient documentation • Non-hallucination • Agentic workflows Healthcare is one of the highest-stakes domains you can test an AI on And Grok is now competing at the very top of it

Precipio, Inc. (@PrecipioDx ) (@Nasdaq : $PRPO ) reported revenue of $7.0 million for the second quarter ended June 30, 2026, the highest quarterly revenue in the company’s history and an increase of 22% from $5.7 million in the second quarter of 2025. The specialty cancer diagnostics company validates its technologies clinically in its own laboratory before commercializing them for the global laboratory community. Precipio, Inc. is a B2i Digital (@b2idigital )Featured Company. See the company’s in-depth profile at: Both sides of the business contributed, with pathology services and diagnostic products each growing sequentially: • Revenue surpassed $7 million for the first time in company history, rising from $6.7 million in the first quarter • Product revenue reached $0.9 million, an increase of 21% over the previous high of $750,000 in the fourth quarter of 2025, and pathology revenue reached $6.1 million • Adjusted EBITDA, a non-GAAP measure the company reconciles in the release, was positive at $0.4 million for the quarter • Cash flow from operations was $0.7 million, and cash ended the quarter above $3 million against $1.1 million a year earlier • Management will discuss the quarter on a shareholder call on August 17, 2026 at 5 p.m. ET, followed by a moderated question and answer session The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call. Regarding the cash balance, Ilan Danieli, Chief Executive Officer of Precipio, stated: “We’ve achieved this level of cash without a financing event, demonstrating the strength of our operations. We’re encouraged by the progress we’ve made and believe we are well positioned to continue building on this momentum.” Read the full release: Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services that deliver higher accuracy, improved laboratory workflow, and better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in its laboratory where it designs, tests, validates, and uses these products clinically, then commercializes them as proprietary products that serve the global laboratory community. More information is available at Discover more emerging growth Featured Companies, Featured Experts, and upcoming Featured Conferences at B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at

New from @GoogleResearch and @GoogleDeepMind: AMIE can now conduct real-time video consultations. In a randomized study using simulated consultations, it met clinical performance benchmarks, showing AI’s potential to expand telehealth access. Learn more:

MARC ANDREESSEN WENT ON ROGAN FOR OVER 3 HOURS. HERE ARE THE 17 THINGS WORTH YOUR ATTENTION. 1. AGI is already here, in his view. He says the line got crossed about 3 months ago with GPT-5.5, Claude 4.6, Gemini 3, and Grok 4.3, and nobody noticed because the field moves too fast to register milestones anymore. 2. For almost any topic, he says the top models now give him better answers than the world-class experts he could call by phone, and he can call almost anyone. Worth noting he has not published data behind this, and a separate Nature Medicine study on a comparable AI health tool found it missed real emergencies more than half the time. Take the claim seriously, verify it yourself. 3. His claim on doctors: they are already using ChatGPT in the exam room, typing your symptoms in the moment you stop talking. His actual quote: "at that point you're asking the question of like, what do I need you for." 4. Reportedly, when AI declines to answer something, he tells it he's writing a novel to get past the refusal. 5. Reportedly, his technique for hard topics is escalating simplicity: explain it like I'm 10, then 5, then 2, until it clicks. 6. Reportedly, instead of asking for the "right" answer, he has the AI steelman both sides of a hard question, then decides himself. 7. Reportedly, for big questions he has the AI role-play a panel of experts arguing with each other. 8. His broader point: the moment you think "I don't know how to figure this out" is exactly when most people give up, and exactly when you should open the AI instead. 9. His view: the only real skill left is knowing what to ask. The bottleneck is in your head, not the model. 10. He describes sending AI photos, rashes, blood tests, for a fast second opinion, since current models read images directly. 11. He points to CBT as the one clinically proven therapy type that AI can plausibly deliver on its own, meaning real therapeutic support becomes freely available at scale. 12. He cites AI cracking previously unsolved math problems, with early signs of the same happening in physics, chemistry, and biology. 13. Reportedly, he claims the top AI coders in Silicon Valley now earn as much as $50 million a year, which he uses as a signal of how large this shift actually is. 14. Reportedly, a friend paid to sequence his own DNA, fed it to an AI along with blood work and wearable data, and got back a working health dashboard. 15. Reportedly, another friend set up cameras in his home jiu-jitsu gym so AI could review his sparring and give him technique notes. 16. He coined the term "AI vampire" for the pattern of people working more and sleeping less because AI keeps making more output possible, a real term he used, though the framing around it varies by account. 17. His extrapolation: one person eventually running many AI coding agents, each reviewing the others, describing this as close, not years out. Watch the full interview before treating any single number as settled. Several of these are Andreessen's stated views and anecdotes, not independently verified facts. Follow @cyrilXBT for every AI insight worth your attention the moment it surfaces.